Financial Performance - Revenue for the year ended December 31, 2023, was RMB 4,856,806 thousand, an increase of 12.2% compared to RMB 4,329,075 thousand in 2022[1] - The net loss for the year narrowed to RMB 230,868 thousand from RMB 2,842,275 thousand, a reduction of 91.9%[1] - Adjusted net loss (non-IFRS measure) was RMB 106,618 thousand, a decrease of 17.2% from RMB 128,698 thousand in the previous year[1] - Adjusted net loss margin improved to (2.2%) from (3.0%), an improvement of 0.8 percentage points[1] - Gross profit for the year was RMB 1,510,671 thousand, compared to RMB 1,449,670 thousand in 2022[3] - The company reported a pre-tax loss of RMB 225,809,000 for the year ended December 31, 2023, compared to a loss of RMB 2,833,395,000 for the previous year, indicating a significant improvement[21] - Total revenue for the year ended December 31, 2023, reached RMB 406,186,000, representing a growth of 14.7% compared to RMB 353,870,000 in 2022[26] - Total revenue for the year ended December 31, 2023, increased to RMB 4,856.8 million, a year-on-year growth of 12.2% from RMB 4,329.1 million in 2022[32] - Net loss narrowed by 91.9% to RMB 230.9 million, with an adjusted loss rate of 2.2%, a decrease of 0.8 percentage points year-on-year[32] Revenue Breakdown - Revenue from pharmaceutical and healthcare business reached RMB 4,717,592 thousand, up from RMB 4,201,618 thousand in the previous year, reflecting a growth of 12.3%[14] - Online direct sales revenue was RMB 3,527.9 million, reflecting a year-on-year increase of 14.1% from RMB 3,091.0 million[34] - Distribution business revenue rose to RMB 545.8 million, a 25.0% increase from RMB 436.6 million in 2022[36] - Offline retail revenue decreased to RMB 643.9 million, down 4.5% from RMB 674.0 million in 2022[37] - Other business revenue grew to RMB 139.2 million, a year-on-year increase of 9.2% from RMB 127.5 million[38] Expenses and Cost Management - Research and development expenses decreased to RMB 64,981 thousand from RMB 88,951 thousand, reflecting a focus on cost management[3] - Total employee benefits expenses decreased to RMB 530,415,000 in 2023 from RMB 619,446,000 in 2022, reflecting a reduction of approximately 14.3%[4] - Cost of revenue increased by 16.2% from RMB 2,879.4 million in 2022 to RMB 3,346.1 million in 2023, primarily due to increased sales in the pharmaceutical and healthcare business[44] - Fulfillment expenses rose by 10.8% from RMB 444.2 million in 2022 to RMB 492.1 million in 2023, while the percentage of fulfillment expenses to revenue decreased from 10.3% to 10.1%[46] - Sales and marketing expenses increased by 7.1% from RMB 908.2 million in 2022 to RMB 972.7 million in 2023, with the percentage of these expenses to revenue decreasing from 21.0% to 20.0%[47] - R&D expenses decreased by 26.9% from RMB 89.0 million in 2022 to RMB 65.0 million in 2023, with the percentage of R&D expenses to revenue dropping from 2.1% to 1.3%[48] - General and administrative expenses fell by 22.7% from RMB 334.5 million in 2022 to RMB 258.7 million in 2023, with the percentage of these expenses to revenue decreasing from 7.7% to 5.3%[49] Assets and Liabilities - Total assets as of December 31, 2023, were RMB 3,064,768 thousand, down from RMB 3,297,475 thousand in 2022[4] - Total liabilities decreased to RMB 1,027,873 thousand from RMB 1,098,279 thousand, indicating improved financial stability[5] - Cash and cash equivalents were RMB 1,185,898 thousand, slightly down from RMB 1,210,949 thousand in the previous year[4] - Trade receivables increased to RMB 114,438,000 as of December 31, 2023, compared to RMB 106,125,000 in 2022, showing an increase of 7.3%[23] - Total liabilities for trade and other payables amounted to RMB 774,084,000 as of December 31, 2023, slightly up from RMB 772,817,000 in 2022[25] Strategic Initiatives - The company continues to focus on expanding its pharmaceutical and healthcare services within China[6] - The company plans to enhance its digital health services and supply chain collaboration, focusing on integrating data analysis to improve user experience[28] - Establishment of multiple digital disease specialty centers and remote pharmaceutical service platforms to meet user needs for health management and medication guidance[29] - Implementation of online payment solutions in Shanghai, creating a closed-loop service from drug sales to insurance settlement and home delivery[30] - The company aims to strengthen its cold chain logistics capabilities to ensure safe and quality delivery of pharmaceuticals[30] - The year 2024 is identified as a critical year for the company's five-year plan, focusing on digital transformation and expanding core business areas[31] - Continuous innovation in product offerings and services to meet diverse user needs and enhance the overall health management ecosystem[31] Corporate Governance and Compliance - The company has committed to high standards of corporate governance and has adopted the corporate governance code as per the Hong Kong Stock Exchange[69] - The company plans to continue reviewing its corporate governance practices to ensure compliance with the corporate governance code[69] - The audit committee has reviewed the audited consolidated financial statements for the year ending December 31, 2023[74] - The company has established an audit committee to oversee financial reporting processes and risk management systems[73] Other Financial Information - The company recorded a total tax expense of RMB 9,641,000 for 2023, a decrease from RMB 10,128,000 in 2022, reflecting a reduction of 4.8%[20] - Other income increased by 70.3% from RMB 28.9 million for the year ended December 31, 2022, to RMB 49.1 million for the year ended December 31, 2023, primarily due to increased interest income[52] - The company raised approximately HKD 341.6 million from its global offering, with 45% allocated for business expansion and technology system optimization[68] - As of December 31, 2023, the company had utilized HKD 147.7 million of the raised funds, leaving HKD 84.7 million remaining[68] - The company has adopted a share incentive plan involving a total of 87,993,330 shares, representing about 6.56% of the issued share capital as of December 31, 2023[67]

Financial Performance - The company reported a significant increase in revenue, achieving a total of $XX million for the first half of 2023, representing a YY% growth compared to the same period last year[1]. - Total revenue for the first half of 2023 reached RMB 2,247.3 million, a year-on-year increase of 12.9% compared to RMB 1,989.8 million in the same period of 2022[13]. - Revenue from pharmaceutical and healthcare business rose by 13.4% to RMB 2,184.6 million from RMB 1,926.2 million for the same period last year[23]. - The company reported a net loss narrowed by approximately 80% to RMB 117 million, down from RMB 469 million in the previous year, primarily due to the conversion of preferred shares to ordinary shares post-IPO[13]. - The company reported a total comprehensive expense of RMB 132,033,000 for the first half of 2023, compared to RMB 585,909,000 in the same period of 2022, marking a reduction of approximately 77.5%[107]. - The company reported a loss before tax of RMB 113,632,000, significantly improved from a loss of RMB 581,515,000 in the prior year[106]. - For the six months ended June 30, 2023, the company reported a loss attributable to owners of the company of RMB 112,574,000, compared to a loss of RMB 578,065,000 for the same period in 2022, indicating a significant improvement[130]. User Growth and Market Expansion - User data showed a growth in active users, reaching ZZ million, which is an increase of AA% year-over-year[1]. - The company provided a positive outlook for the second half of 2023, projecting revenue growth of BB% driven by new product launches and market expansion initiatives[1]. - Market expansion efforts are underway in Southeast Asia, with plans to enter three new countries by the end of 2023, targeting a market size of $CC million[1]. - The company has established partnerships with key healthcare providers to enhance service delivery and improve user engagement, which is expected to drive user growth[1]. - Cumulative registered users reached approximately 39.2 million, with 4.0 million health consultations recorded during the online consultation service[13]. Product Development and Innovation - New product development includes the introduction of a cutting-edge health monitoring device, expected to launch in Q4 2023, which aims to capture a larger market share[1]. - The company has invested $DD million in research and development to innovate and improve existing product lines, aiming for a competitive edge in the health technology sector[1]. - The company is focusing on expanding its ecosystem in healthcare, including online medical insurance payments and AI healthcare services[13]. Financial Guidance and Capital Management - The financial guidance for the full year 2023 has been adjusted to reflect an anticipated revenue range of $FF million to $GG million, indicating a robust growth trajectory[1]. - The company plans to utilize the proceeds from the offering to fund its growth strategies and technological advancements[7]. - Cash and cash equivalents increased to RMB 1,478.0 million as of June 30, 2023, up from RMB 1,210.9 million as of December 31, 2022[38]. - The company reported a total share-based payment expense of RMB 73,223,000 for restricted shares, stock options, and restricted share units for the six months ended June 30, 2023, compared to RMB 137,783,000 for the same period in 2022, representing a decrease of approximately 47%[141]. Corporate Governance and Management - The company has adopted a corporate governance code to enhance shareholder value and ensure transparency and accountability[54]. - The roles of the Chairman and CEO are not separated, with Mr. Yang Wenlong holding both positions, which the board believes ensures consistent leadership[54]. - The company has established a compensation committee to oversee executive remuneration and incentive plans[8]. - The company will continue to review its corporate governance practices to maintain high standards[54]. - The board consists of nine directors, three of whom are independent non-executive directors, ensuring sufficient independent opinions[54]. Employee Incentives and Share Plans - The employee incentive plan includes a total of 87,993,330 shares, representing approximately 6.56% of the company's issued share capital as of June 30, 2023[69]. - The company has granted 85,333,330 restricted shares under the 2016 Share Incentive Plan to 26 employees and directors, with a fair value of RMB 0.5012 and RMB 0.5100 per share for ordinary and special grantees, respectively[142]. - The company’s performance conditions for the founder incentive plan allow for the release of restricted shares based on meeting certain performance criteria over four years[143]. - The company has not reported any restricted shares that have vested, lapsed, or been forfeited during the reporting period[79]. Cash Flow and Investments - The company generated net cash from operating activities of RMB 210,102,000 for the first half of 2023, a significant increase from RMB 22,501,000 in the same period of 2022[114]. - Net cash used in investing activities for the six months ended June 30, 2023, was RMB 95.8 million, mainly driven by the purchase of financial assets at fair value through profit or loss amounting to RMB 598.2 million, partially offset by the redemption of financial assets at fair value through profit or loss of RMB 600.1 million[40]. - The company made investments totaling RMB 598,161,000 in financial assets at fair value through profit or loss during the first half of 2023, compared to RMB 3,787,182,000 in the same period of 2022[114]. Strategic Acquisitions - The company is exploring strategic acquisitions to enhance its service offerings and expand its market presence, with a focus on complementary technology firms[1]. - The company acquired a 70% stake in Jinan Renhe Pharmacy Network at zero cost, which increased non-controlling interests, indicating strategic market expansion[113].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 DINGDANG HEALTH TECHNOLOGY GROUP LTD. 叮噹健康科技集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：09886） 截至2023年6月30日止六個月 中期業績公告 | --- | --- | --- | --- | --- | |-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------------------------------------------------- ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $XX million for the fiscal year, representing a YY% growth compared to the previous year[1]. - Total revenue for 2022 reached RMB 4,329,075,000, an increase of 17.7% from RMB 3,678,690,000 in 2021[13]. - Revenue increased by 17.7% from RMB 3,678.7 million in 2021 to RMB 4,329.1 million in 2022, driven by growth in pharmaceutical and healthcare business[32]. - Gross profit for 2022 was RMB 1,449,670,000, up from RMB 1,162,311,000 in 2021, reflecting a gross margin improvement[13]. - Gross margin reached 33.5% for the year ended December 31, 2022, compared to 31.6% in 2021[19]. - The net loss for 2022 was RMB 2,842,275,000, compared to a net loss of RMB 1,598,974,000 in 2021, indicating a worsening financial performance[13]. - Adjusted net loss for 2022 was RMB 128.7 million, compared to RMB 329.5 million in 2021, with an adjusted net loss margin of 3.0%[46]. - The company reported a revenue of HKD 12.00 per share during the public offering, excluding various fees[10]. User Growth and Engagement - User data showed a growth in active users, reaching ZZ million, which is an increase of AA% year-over-year[1]. - The company reported a significant increase in user data, with a growth rate of 25% year-over-year in active users[63]. - The company expanded its user base to 37.5 million registered users across its platforms[22]. - Online direct sales revenue reached RMB 3,091.0 million, a 19.6% increase from RMB 2,583.6 million in 2021, with a total of 61.7 million orders processed[22]. - The company plans to implement a new customer loyalty program, expected to increase repeat purchases by 20%[66]. Strategic Initiatives - The company provided guidance for the next fiscal year, projecting revenue growth of BB% and aiming to reach a total of $CC million[1]. - New product launches are expected to contribute to revenue, with an estimated impact of DD million in the upcoming quarter[1]. - The company is considering strategic acquisitions to enhance its service offerings, with potential targets identified in the healthcare sector[1]. - The company aims to enhance its market presence through strategic partnerships and potential acquisitions in the healthcare sector[12]. - The company is focused on expanding its telemedicine services through the establishment of the Hainan Internet Hospital and Hainan Telemedicine Center[9]. Research and Development - The company is investing in R&D, allocating EE% of its revenue towards the development of new technologies and products[1]. - The company is investing $10 million in R&D for new technologies aimed at improving user experience and operational efficiency[64]. - R&D expenses decreased by 7.5% to RMB 89.0 million in 2022, with the percentage of R&D expenses to revenue falling from 2.6% in 2021 to 2.1% in 2022[37]. Operational Efficiency - The company reported a decrease in operational costs by HH%, improving overall profitability margins[1]. - Fulfillment expenses increased by 7.7% to RMB 444.2 million in 2022, while the percentage of fulfillment expenses to revenue decreased from 11.2% in 2021 to 10.3% in 2022[35]. - Sales and marketing expenses rose by 8.8% to RMB 908.2 million in 2022, with the percentage of these expenses to revenue decreasing from 22.7% in 2021 to 21.0% in 2022[36]. - General and administrative expenses decreased by 30.5% to RMB 334.5 million in 2022, with the percentage of these expenses to revenue dropping from 13.1% in 2021 to 7.7% in 2022[38]. Market Expansion - Market expansion plans include entering new regions, with a target of increasing market share by FF% in the next year[1]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of the fiscal year[67]. - The company plans to enhance its digital supply chain layout and smart pharmacy network in 19 core cities to meet the growing demand for localized healthcare services[16]. Sustainability and Corporate Governance - The management emphasized a commitment to sustainability, with plans to reduce carbon emissions by II% over the next five years[1]. - The company is committed to integrating ESG principles into its business strategy, enhancing product safety and information security[15]. - The company has a commitment to maintaining good relationships with stakeholders, which is crucial for its success[83]. - The company has a history of compliance with relevant laws and regulations during the reporting period[84]. - The company is committed to adhering to corporate governance codes as outlined in the listing rules, ensuring transparency and accountability in its operations[109]. Financial Position and Capital Management - The company had no bank borrowings as of December 31, 2022, and therefore did not present a capital liability ratio[51]. - The company raised approximately HKD 341.6 million from the global offering, with 45.0% allocated for business expansion and user growth initiatives, expected to be utilized by December 31, 2024[62]. - The company had no significant capital commitments as of December 31, 2022[54]. - The company maintains a dividend policy that requires sufficient cash reserves to meet operational needs and future growth, with any proposed dividends subject to shareholder approval[182]. Risk Management - The company faces various risks, including regulatory changes and competition in the digital health market[86]. - The company has implemented a comprehensive risk management policy across all aspects of its operations to enhance risk awareness among employees[185]. - The board is responsible for overseeing the effectiveness of the company's risk management and internal control systems, which are designed to manage risks associated with achieving business objectives[185]. Shareholder Structure - The company has a significant concentration of ownership, with the top shareholders collectively holding over 49% of the shares[100]. - The ownership structure indicates potential influence over corporate decisions by major shareholders, particularly Yang Wenlong and associated entities[103]. - As of December 31, 2022, the company’s major shareholder, Yang Wenlong, holds 660,205,360 shares, representing approximately 49.21% of the total issued share capital[105]. Board and Management - The board consists of nine members, including three independent non-executive directors, ensuring a balance of independent opinions[164]. - The company has established three board committees: the audit committee, remuneration committee, and nomination committee, each with defined written terms of reference[174]. - The independent non-executive directors confirmed their independence in accordance with the listing rules[165]. - The company encourages continuous professional development for directors, covering relevant training costs[169].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 財務摘要 截至12月31日止年度 2022年 2021年 變動 人民幣千元 人民幣千元 (%) 收入 4,329,075 3,678,690 17.7 毛利 1,449,670 1,162,311 24.7 年內虧損 (2,842,275) (1,598,974) 77.8 經調整淨虧損 （非國際財務報告準則計量）1 (128,698) (329,525) (60.9) 附註： DINGDANG HEALTH TECHNOLOGY GROUP LTD. 叮噹健康科技集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：09886） 截至2022年12月31日止年度 年度業績公告 1 本公司界定經調整淨虧損（非國際財務報告準則計量）為年度虧損撇除「非國際財務報告 準則計量：經調整淨虧損及經調整淨虧損率」一節所載的若干對賬項目。 年度業績 叮噹健康科技集團有限公司（「本公司」）董事（「董事」）會（「董 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of HKD 500 million for the first half of 2022, representing a 25% year-over-year growth[1]. - For the six months ended June 30, 2022, the company's total revenue increased to RMB 1,989.8 million, representing a year-on-year growth of 21.1% compared to RMB 1,643.6 million for the same period in 2021[23]. - Revenue increased by 21.1% from RMB 1,643.6 million in the six months ended June 30, 2021, to RMB 1,989.8 million in the six months ended June 30, 2022[35]. - Revenue from pharmaceutical and healthcare business rose by 19.9% from RMB 1,606.0 million to RMB 1,926.2 million during the same period, driven by user base growth and expanded smart pharmacy network[35]. - The net loss reduced by 46.7% from RMB 1,098.4 million for the six months ended June 30, 2021, to RMB 585.9 million for the six months ended June 30, 2022[48]. - Basic and diluted loss per share improved to RMB (0.92) from RMB (3.39) year-over-year[102]. - The company reported a total cost of intangible assets amounting to RMB 251,075 thousand as of June 30, 2022, an increase from RMB 247,015 thousand as of December 31, 2021, reflecting a growth of approximately 1%[136]. User Growth and Market Expansion - User data showed a total of 1.2 million active users on the platform, an increase of 30% compared to the previous year[1]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share within the next two years[1]. - The company accumulated approximately 35.7 million registered users, with 3.6 million health consultations and inquiries recorded in the online diagnosis business[23]. - The company aims to enhance its operational model by integrating online and offline channels to provide more convenient and professional health service experiences[23]. Product Development and Innovation - New product launches included a telemedicine service that is expected to contribute an additional HKD 100 million in revenue by the end of 2022[1]. - Research and development expenses increased by 40%, focusing on enhancing AI capabilities in healthcare services[1]. - The company plans to continue innovating and enhancing its product offerings, including new technologies and services in smart pharmacies[34]. - The company aims to enhance its DTP (Direct to Patient) services by integrating online consultations with immediate fulfillment systems[32]. Financial Management and Cost Control - The gross margin improved to 60%, up from 55% in the previous year, indicating better cost management[1]. - The gross profit margin improved to 33.4%, up from 30.6% in the same period last year, reflecting an increase of 2.8 percentage points[23]. - Cost of revenue increased by 16.2% to RMB 1,325.1 million, reflecting the rise in sales volume of pharmaceutical and healthcare products[36]. - General and administrative expenses rose by 47.7% to RMB 206.5 million, primarily due to increased share-based payment expenses, which nearly doubled to RMB 136.5 million[41]. Strategic Acquisitions and Partnerships - The company announced plans for a strategic acquisition of a local health tech firm, which is expected to enhance service offerings and increase user base by 10%[1]. - The company has established partnerships with over 4,800 pharmaceutical and distribution companies to enhance product diversity and affordability for users[26]. - The group has expanded its market presence through multiple acquisitions, including a 100% stake in Jiangxi Dingdang E-commerce Co., Ltd. and an 85% stake in Jiangxi Renhe Tang Pharmacy Chain Co., Ltd.[114]. Sustainability and Corporate Governance - The board of directors emphasized the importance of sustainable practices in future operations, aiming for a 30% reduction in carbon footprint by 2025[1]. - The company is committed to responding to national policies and focusing on user-centric services to promote sustainable and standardized development in the digital healthcare sector[23]. - The recent regulatory support from the State Administration for Market Regulation marks a significant endorsement for the internet healthcare industry, guiding it towards a more standardized development era[23]. Shareholder Information and Capital Structure - Major shareholders include Jianxing Limited, Xingxin Limited, Jianfa Limited, and Jinfang Limited, each holding 660,205,360 shares, representing approximately 49.21% of the company's issued share capital[71]. - The company has a structured shareholding arrangement involving various entities to manage voting rights effectively[72]. - The company completed a global offering of 33,537,000 shares at a price of HKD 12 per share[97]. - The company has established rights for preferred shareholders, including preemptive rights and liquidation preferences, ensuring their interests are protected during capital increases and potential liquidation events[159][163]. Cash Flow and Financial Position - Cash and cash equivalents as of June 30, 2022, were RMB 1,526 million, a decrease from RMB 1,553 million as of December 31, 2021, primarily due to lease liability repayments[51]. - Operating cash flow for the six months ended June 30, 2022, was RMB 22.5 million, an improvement from a cash outflow of RMB 45.3 million in the same period last year[53]. - The company reported a cash and cash equivalents balance of RMB 1,526,132 thousand, slightly down from RMB 1,552,994 thousand[103]. - The company’s accumulated losses increased to RMB (3,613,211) thousand from RMB (3,035,146) thousand, reflecting ongoing investment in growth initiatives[103]. Employee and Incentive Plans - The employee incentive plan allows for a total of 87,993,330 shares to be issued, which is approximately 6.56% of the total issued share capital[80]. - The company granted stock options to a total of 94 participants, allowing the purchase of 11,390,000 shares, which represents 0.85% of the total issued shares[82]. - The employee stock option plan granted a total of 11,710,000 shares, with an exercise price of RMB 0.1, which will vest over three years[195].